References
- Van Der Werf C, Nederend I, Hofman N, Van Geloven N, Ebink C, Frohn-Mulder IME, et al. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: Disease penetrance and expression in cardiac ryanodine receptor mutation–carrying relatives. Circ Arrhythm Electrophysiol. 2012;5(4):748–56.
- Abbas M, Miles C, Behr E. Catecholaminergic polymorphic ventricular tachycardia. Arrhythm Electrophysiol Rev. 2022;11:e20.
- Napolitano C, Mazzanti A, Bloise R, Priori SG. Catecholaminergic polymorphic ventricular tachycardia [Internet]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 1993 [cited 2024 Nov 12]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1289/
- Roston TM, Yuchi Z, Kannankeril PJ, Hathaway J, Vinocur JM, Etheridge SP, et al. The clinical and genetic spectrum of catecholaminergic polymorphic ventricular tachycardia: findings from an international multicentre registry. EP Europace. 2018;20(3):541–7.
- Pérez-Riera AR, Barbosa-Barros R, De Rezende Barbosa MPC, Daminello-Raimundo R, De Lucca AA, De Abreu LC. Catecholaminergic polymorphic ventricular tachycardia, an update. Ann Noninvasive Electrocardiol. 2018;23(4):e12512.
- Aggarwal A, Stolear A, Alam MM, Vardhan S, Dulgher M, Jang SJ, et al. Catecholaminergic polymorphic ventricular tachycardia: Clinical characteristics, diagnostic evaluation and therapeutic strategies. J Clin Med. 2024;13(6):1781.
- Postma AV. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet. 2005;42(11):863–70.
- Priori SG, Napolitano C, Memmi M, Colombi B, Drago F, Gasparini M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation. 2002;106(1):69–74.
- Bauce B, Rampazzo A, Basso C, Bagattin A, Daliento L, Tiso N, et al. Screening for ryanodine receptor type 2 mutations in families with effort-induced polymorphic ventricular arrhythmias and sudden death. J Am Coll Cardiol. 2002;40(2):341–9.
- Haugaa KH, Leren IS, Berge KE, Bathen J, Loennechen JP, Anfinsen OG, et al. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening. Europace. 2010;12(3):417–23.
- Roston M, Kallas D, Davies B, Franciosi S, De Souza AM, Laksman ZW, et al. Burst exercise testing can unmask arrhythmias in patients with incompletely penetrant catecholaminergic polymorphic ventricular tachycardia. JACC Clin Electrophysiol. 2021;7(4):437–41.
- Hayashi M, Denjoy I, Hayashi M, Extramiana F, Maltret A, Roux-Buisson N, et al. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands. Europace. 2012;14(9):1344–51.
- Tester DJ, Ackerman JP, Giudicessi JR, Ackerman NC, Cerrone M, Delmar M, et al. Plakophilin-2 truncation variants in patients clinically diagnosed with catecholaminergic polymorphic ventricular tachycardia and decedents with exercise-associated autopsy-negative sudden unexplained death in the young. JACC Clin Electrophysiol. 2019;5(1):120–7.
- Imberti JF, Underwood K, Mazzanti A, Priori SG. Clinical challenges in catecholaminergic polymorphic ventricular tachycardia. Heart Lung Circ. 2016;25(8):777–83.
- Zeppenfeld K, Tfelt-Hansen J, De Riva M, Winkel BG, Behr ER, Blom NA, et al. 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997–4126.
- Heidbuchel H, Adami PE, Antz M, Braunschweig F, Delise P, Scherr D, et al. Recommendations for participation in leisure-time physical activity and competitive sports in patients with arrhythmias and potentially arrhythmogenic conditions: Part 1: Supraventricular arrhythmias. Eur J Prev Cardiol. 2021;28(14):1539–51.
- Ackerman MJ, Zipes DP, Kovacs RJ, Maron BJ. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 10: The cardiac channelopathies. J Am Coll Cardiol. 2015;66(21):2424–8.
- Levine BD, Baggish AL, Kovacs RJ, Link MS, Maron MS, Mitchell JH. Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: Task Force 1: Classification of sports: Dynamic, static, and impact: A scientific statement from the American Heart Association and American College of Cardiology [Internet]. Circulation. 2015 [cited 2024 Nov 12];132(22). Available from: https://www.ahajournals.org/doi/10.1161/CIR.0000000000000237
- Heidbuchel H, Arbelo E, D’Ascenzi F, Borjesson M, Boveda S, Castelletti S, et al. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part 2: Ventricular arrhythmias, channelopathies, and implantable defibrillators. Europace. 2021;23(1):147–8.